Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance) is a research paper published in Investigational New Drugs (2021). On theSindex it has a DataRank of 0.360. It has been cited 10 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: CA090628
National Institutes of Health
Grant: U10CA180821
National Institutes of Health
Grant: U10CA180882
National Institutes of Health
Grant: UG1CA232760
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
National Institutes of Health
Grant: 5K12CA090628-25
Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic
National Institutes of Health
Grant: 3UG1CA232760-06S1
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)
National Institutes of Health
Grant: 1Z01BC001002-01
CYCLIC ADENOSINE MONOPHOSPHATE ELEVATION--EFFECTS ON NEUTROPHIL MOTILITY
National Institutes of Health
Grant: 5U10CA180882-02
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
Fields of Study
Keywords
Sustainable Development Goals